Profile picture

Doctor Gerald Chi

Harvard Medical School, Boston (United States of America)
Follow
Biography
Dr Chi is a clinical research staff scientist at Beth Israel Deaconess Medical Center and instructor in medicine at Harvard Medical School. Dr. Chi has served as an investigator in clinical studies focusing on coronary artery disease, atrial fibrillation, stroke, venous thromboembolism, and dyslipidemia.
Logo ESC

Contributor content

Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial
Presentation
Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial
Effect of procedure and lesion characteristics on bleeding and ischemic outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: results from the PIONEER AF-PCI trial
Presentation
Effect of procedure and lesion characteristics on bleeding and ischemic outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: results from the PIONEER AF-PCI trial
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis
Presentation
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy.
Presentation
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy.
Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy
Presentation
Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy

ESC 365 is supported by